Similarly, Snooke et al. have recently demonstrated that Shp1 knockdown potentiates the antitumor activity of T-cells responding to low-affinity tumor antigen, particularly in combinatorial studies blocking both PD-1 and CTLA-4 (97). This evidence concerns the gene PDCD1 and neoplasm.